NCT04629339终止2 期
A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 16
- 试验地点
- 19
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to comprehend and willingness to sign a written ICF for the study.
- •Participants with following tumor types : non small cell lung cancer, renal cell carcinoma, urothelial carcinoma, hepatocellular carcinoma and melanoma
- •Measurable disease per RECIST v1.
- •ECOG performance status of 0 to 1 for all tumor types. Urothelial carcinoma allows ECOG of 0 to
- •Histologically or cytologically confirmed disease-specific diagnosis as per protocol.
- •Willingness to avoid pregnancy or fathering children
排除标准
- •Prior receipt of an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or treatment with an immune modulator (eg, CTLA-4, GITR, LAG3, TIM3, OX40, ICOS, IL2, 4-1BB, CAR-T).
- •Receipt of any anticancer therapy or participation in another interventional clinical study.
- •Radiotherapy within 14 days of first dose of study treatment.
- •Concomitant treatment with moderate and potent CYP3A4/CYP3A5 inhibitors or inducers.
- •Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of anemia not requiring transfusion support and any grade of alopecia). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with the medical monitor.
- •Participant has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.
- •Participants with laboratory values outside of protocol defined ranges Active malignancy of a type not included in the study population requiring treatment.
- •Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or equivalent).
- •Evidence of interstitial lung disease or active, noninfectious pneumonitis.
- •Untreated or known active CNS metastases and/or carcinomatous meningitis.
- •With the exception of participants with HCC, known active HAV, HBV, or HCV infection, as defined by elevated transaminases with the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior immunization).
- •Active infection requiring systemic therapy.
- •Receipt of systemic antibiotics within 28 days of first dose of study treatment
- •Probiotic usage during screening and throughout the study treatment period.
- •Participants who are known to be HIV-positive.
- •Participants with impaired cardiac function or clinically significant cardiac disease.
- •History or presence of an ECG finding that, in the investigator's opinion, is clinically meaningful.
- •Female participant is pregnant or breastfeeding within the projected duration of the study, starting with the screening visit through the 90-day safety follow-up, or male participant is expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 100 days after the last dose of study treatment.
- •Has received a live vaccine within 90 days of the planned start of study drug.
- •Current use of a prohibited medication as described in protocol.
- •Life expectancy < 3 months.
- •Known hypersensitivity or severe reaction to any component of study drug or formulation components.
- •History of organ transplant, including allogeneic stem cell transplantation.
- •Inability to swallow tablets or any condition of the upper gastrointestinal tract that precludes administration of oral medications.
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
研究组 & 干预措施
INCB086550
Experimental
INCB086550 will be administered orally twice a day.
干预措施: INCB086550 (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: up to 733 days
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), confirmed by ≥1 repeat assessment ≥28 days later, according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
次要结局
- Disease Control Rate (DCR)(up to 733 days)
- Duration of Response (DOR)(up to 733 days)
- Number of Participants With Any Treatment-emergent Adverse Event (TEAE)(up to 823 days)
- Number of Participants With Any ≥Grade 3 TEAE(up to 823 days)
研究者
研究点 (19)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid TumorsImmune Checkpoint Inhibitor–Naïve Selected Solid TumorsMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864EUCTR2020-000157-27-HUIncyte Corporation304
进行中（未招募）
1 期
A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid TumorsEUCTR2020-000157-27-BGIncyte Corporation304
进行中（未招募）
1 期
A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid TumorsImmune Checkpoint Inhibitor–Naïve Selected Solid TumorsMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864EUCTR2020-000157-27-ROIncyte Corporation304
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult ParticipantHealthy ParticipantsNCT06213818Incyte Corporation137
终止
2 期
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaRefractory Hodgkin LymphomaRecurrent Adult Hodgkin's LymphomaNCT02456675Incyte Corporation8